GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Operating Cash Flow per Share

Biogen (MEX:BIIB) Operating Cash Flow per Share : MXN193.03 (TTM As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Biogen Operating Cash Flow per Share?

Biogen's operating cash flow per share for the three months ended in Mar. 2024 was MXN62.93. Biogen's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was MXN193.03.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Biogen was -1.90% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -26.00% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -23.60% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 1.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Biogen's Operating Cash Flow per Share or its related term are showing as below:

MEX:BIIB' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -36.9   Med: 20.7   Max: 203.4
Current: -26

During the past 13 years, Biogen's highest 3-Year average Operating Cash Flow per Share Growth Rate was 203.40% per year. The lowest was -36.90% per year. And the median was 20.70% per year.

MEX:BIIB's 3-Year OCF Growth Rate is ranked worse than
83.84% of 792 companies
in the Drug Manufacturers industry
Industry Median: 6.8 vs MEX:BIIB: -26.00

Biogen Operating Cash Flow per Share Historical Data

The historical data trend for Biogen's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Operating Cash Flow per Share Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Cash Flow per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 712.39 521.63 499.12 184.85 180.38

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 56.52 57.38 71.26 1.45 62.93

Competitive Comparison of Biogen's Operating Cash Flow per Share

For the Drug Manufacturers - General subindustry, Biogen's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Biogen's Price-to-Operating-Cash-Flow falls into.



Biogen Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Biogen's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )=Cash Flow from Operations (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=26262.556/145.600
=180.37

Biogen's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )=Cash Flow from Operations (Q: Mar. 2024 )/Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
=9181.048/145.900
=62.93

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN193.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Biogen's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Industry
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (MEX:BIIB) Headlines

From GuruFocus

Q2 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2023 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at Stifel CNS Days (Virtual) Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at Stifel CNS Days (Virtual) Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Q4 2021 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024